Search research articles
Contact Us
Filters
Showing results (231-240 of 265) with videos related to
Page
of 27
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
December 31, 2021
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
D Rodríguez-Abreu, M Cobo, S García-Román, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 15, 2018
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
S Gadgeel, S Peters, T Mok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1997
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival
F Graus, J Dalmou, R Reñé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
F Cardenal, M P López-Cabrerizo, A Antón, et al.
Schizophrenia Research
|
February 19, 2018
Frontal and temporal cortical volume, white matter tract integrity, and hemispheric asymmetry in schizotypal personality disorder
Chi C Chan, Philip R Szeszko, Edmund Wong, et al.
Clinical Lung Cancer
|
January 22, 2004
Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial
E Felip, R Rosell, V Alberola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2007
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
R Rosell, G Robinet, A Szczesna, et al.
Psychopharmacology
|
January 14, 2023
Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetine
Daniel R Rosell, Mark Slifstein, Judy Thompson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 19, 2020
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T Mok, D R Camidge, S M Gadgeel, et al.
Psychopharmacology
|
June 24, 2020
Amphetamine-induced striatal dopamine release in schizotypal personality disorder
Judy L Thompson, Daniel R Rosell, Mark Slifstein, et al.
Page
of 27
Search research articles
Search
Showing results (231-240 of 265) with videos related to
Sort By:
Page
of 27
Lung Cancer (Amsterdam, Netherlands)
|
December 31, 2021
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC
D Rodríguez-Abreu, M Cobo, S García-Román, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 15, 2018
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
S Gadgeel, S Peters, T Mok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 1, 1997
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival
F Graus, J Dalmou, R Reñé, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
F Cardenal, M P López-Cabrerizo, A Antón, et al.
Schizophrenia Research
|
February 19, 2018
Frontal and temporal cortical volume, white matter tract integrity, and hemispheric asymmetry in schizotypal personality disorder
Chi C Chan, Philip R Szeszko, Edmund Wong, et al.
Clinical Lung Cancer
|
January 22, 2004
Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial
E Felip, R Rosell, V Alberola, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 20, 2007
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer
R Rosell, G Robinet, A Szczesna, et al.
Psychopharmacology
|
January 14, 2023
Serotonin transporter availability in physically aggressive personality disordered patients: associations with trait and state aggression, and response to fluoxetine
Daniel R Rosell, Mark Slifstein, Judy Thompson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 19, 2020
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
T Mok, D R Camidge, S M Gadgeel, et al.
Psychopharmacology
|
June 24, 2020
Amphetamine-induced striatal dopamine release in schizotypal personality disorder
Judy L Thompson, Daniel R Rosell, Mark Slifstein, et al.
Page
of 27